Effects of Torcetrapib in Patients at High Risk for Coronary Events
Why the study?
Does torcetrapib added to atorvastatin reduce major cardiovascular events in patients at high cardiovascular risk?
Population
15,067 patients at high cardiovascular risk
Comparison
Torcetrapib plus atorvastatin vs Atorvastatin alone
Design
RCT, randomized, double-blind
Authors
Discussion
Loading...
Member takes
Implication
Precludes torcetrapib use; challenges CETP inhibition as a strategy to reduce cardiovascular risk.
Structured PICO
Does torcetrapib added to atorvastatin reduce major cardiovascular events in patients at high cardiovascular risk?
P
Population
15,067 patients at high cardiovascular risk
I
Intervention
Torcetrapib plus atorvastatin
C
Comparator
Atorvastatin alone
O
Outcome
Time to the first major cardiovascular event, defined as death from coronary heart disease, nonfatal myocardial infarction, stroke, or hospitalization for unstable anginacomposite
Despite improving lipid profiles, torcetrapib significantly increased the risk of cardiovascular events and all-cause mortality in high-risk patients, leading to premature trial termination.
Cite This Study
Barter et al. (2007) studied this question.